Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309756413> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4309756413 endingPage "8" @default.
- W4309756413 startingPage "1" @default.
- W4309756413 abstract "Background. Glioblastoma (GBM) is a highly prevalent brain tumor characterized by high rates of morbidity, recurrence, and mortality. While temozolomide (TMZ) is commonly used as a first-line treatment for this cancer, the emergence of TMZ resistance limits its utility. The long noncoding RNA HOXA-AS2 reportedly drives GBM progression, but whether it can influence therapeutic resistance to TMZ has yet to be established. Methods. HOXA-AS2 expression was analyzed in TMZ-resistant and sensitive GBM tissue samples and cell lines by qPCR. A siRNA-based approach was used to knock down HOXA-AS2 in GBM cells, after which TMZ resistance was tested. Bioinformatics approaches were used to predict miRNA binding targets of HOXA-AS2, after which a series of luciferase reporter assay and rescue experiments with appropriate miRNA inhibitor/mimic constructs were performed to validate these predictions and to clarify the ability of HOXA-AS2 to regulate chemoresistant activity. Results. TMZ-resistant GBM patients and cell lines exhibited increased HOXA-AS2 expression that was correlated with worse overall survival. Knocking down HOXA-AS2 increased the sensitivity of resistant GBM cells to TMZ. miR-302a-3p was identified as a HOXA-AS2 target confirmed through luciferase reporter assays and rescue experiments, and IGF1 was further identified as a confirmed miR-302a-3p target. In addition, HOXA-AS2 knockdown resulted in a corresponding drop in IGF1 expression consistent with indirect regulation mediated by miR-302a-3p. Conclusion. In summary, these results highlight the role of HOXA-AS2 as a driver of TMZ resistance in GBM through its ability to regulate the miR-302a-3p/IGF1 signaling axis, highlighting this pathway as a promising target for the diagnosis, therapeutic sensitization, and/or treatment of affected patients." @default.
- W4309756413 created "2022-11-29" @default.
- W4309756413 creator A5007322337 @default.
- W4309756413 creator A5061109346 @default.
- W4309756413 creator A5067601314 @default.
- W4309756413 creator A5068835530 @default.
- W4309756413 creator A5086995490 @default.
- W4309756413 creator A5088616206 @default.
- W4309756413 creator A5089568544 @default.
- W4309756413 date "2022-11-21" @default.
- W4309756413 modified "2023-09-28" @default.
- W4309756413 title "LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis" @default.
- W4309756413 cites W2117917811 @default.
- W4309756413 cites W2157733223 @default.
- W4309756413 cites W2162547088 @default.
- W4309756413 cites W2469859047 @default.
- W4309756413 cites W2531789049 @default.
- W4309756413 cites W2540381357 @default.
- W4309756413 cites W2746574162 @default.
- W4309756413 cites W2899888410 @default.
- W4309756413 cites W2942910851 @default.
- W4309756413 cites W2950053207 @default.
- W4309756413 cites W2977041884 @default.
- W4309756413 cites W3006985331 @default.
- W4309756413 cites W3014822529 @default.
- W4309756413 cites W3042236944 @default.
- W4309756413 cites W3093138698 @default.
- W4309756413 cites W3119927734 @default.
- W4309756413 cites W3172735587 @default.
- W4309756413 cites W3178225453 @default.
- W4309756413 cites W3201233863 @default.
- W4309756413 cites W3208931580 @default.
- W4309756413 cites W3211080387 @default.
- W4309756413 cites W4282941661 @default.
- W4309756413 doi "https://doi.org/10.1155/2022/3941952" @default.
- W4309756413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36479381" @default.
- W4309756413 hasPublicationYear "2022" @default.
- W4309756413 type Work @default.
- W4309756413 citedByCount "1" @default.
- W4309756413 countsByYear W43097564132023 @default.
- W4309756413 crossrefType "journal-article" @default.
- W4309756413 hasAuthorship W4309756413A5007322337 @default.
- W4309756413 hasAuthorship W4309756413A5061109346 @default.
- W4309756413 hasAuthorship W4309756413A5067601314 @default.
- W4309756413 hasAuthorship W4309756413A5068835530 @default.
- W4309756413 hasAuthorship W4309756413A5086995490 @default.
- W4309756413 hasAuthorship W4309756413A5088616206 @default.
- W4309756413 hasAuthorship W4309756413A5089568544 @default.
- W4309756413 hasBestOaLocation W43097564131 @default.
- W4309756413 hasConcept C104317684 @default.
- W4309756413 hasConcept C111335760 @default.
- W4309756413 hasConcept C145059251 @default.
- W4309756413 hasConcept C173396325 @default.
- W4309756413 hasConcept C2776194525 @default.
- W4309756413 hasConcept C2777389519 @default.
- W4309756413 hasConcept C502942594 @default.
- W4309756413 hasConcept C54009773 @default.
- W4309756413 hasConcept C54355233 @default.
- W4309756413 hasConcept C81885089 @default.
- W4309756413 hasConcept C86803240 @default.
- W4309756413 hasConceptScore W4309756413C104317684 @default.
- W4309756413 hasConceptScore W4309756413C111335760 @default.
- W4309756413 hasConceptScore W4309756413C145059251 @default.
- W4309756413 hasConceptScore W4309756413C173396325 @default.
- W4309756413 hasConceptScore W4309756413C2776194525 @default.
- W4309756413 hasConceptScore W4309756413C2777389519 @default.
- W4309756413 hasConceptScore W4309756413C502942594 @default.
- W4309756413 hasConceptScore W4309756413C54009773 @default.
- W4309756413 hasConceptScore W4309756413C54355233 @default.
- W4309756413 hasConceptScore W4309756413C81885089 @default.
- W4309756413 hasConceptScore W4309756413C86803240 @default.
- W4309756413 hasLocation W43097564131 @default.
- W4309756413 hasLocation W43097564132 @default.
- W4309756413 hasLocation W43097564133 @default.
- W4309756413 hasOpenAccess W4309756413 @default.
- W4309756413 hasPrimaryLocation W43097564131 @default.
- W4309756413 hasRelatedWork W1961425141 @default.
- W4309756413 hasRelatedWork W2024344351 @default.
- W4309756413 hasRelatedWork W2040830156 @default.
- W4309756413 hasRelatedWork W2544787839 @default.
- W4309756413 hasRelatedWork W2573992804 @default.
- W4309756413 hasRelatedWork W2590702614 @default.
- W4309756413 hasRelatedWork W2781680339 @default.
- W4309756413 hasRelatedWork W3174272423 @default.
- W4309756413 hasRelatedWork W3197962175 @default.
- W4309756413 hasRelatedWork W4311271618 @default.
- W4309756413 hasVolume "2022" @default.
- W4309756413 isParatext "false" @default.
- W4309756413 isRetracted "false" @default.
- W4309756413 workType "article" @default.